Amide Linked Y-Secretase Modulators for Alzheimer's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly those targeting gamma-secretase, face limitations such as unwanted side effects from NSAIDs and low CNS penetration, highlighting the need for novel compounds that modulate gamma-secretase activity effectively.
Innovation Solution
Development of compounds with specific structural formulas that selectively modulate gamma-secretase activity, reducing Aβ42 production without interfering with Notch-processing, thereby offering a therapeutic approach for Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NSAIDs are used to modulate gamma-secretase activity, then Aβ42 production is reduced, but unwanted side effects occur
Solution Approach 1:
The patent modifies the chemical structure of gamma-secretase modulators by changing molecular parameters (introducing specific aromatic rings, amide groups, and stereochemical configurations) to achieve selective modulation of gamma-secretase activity while avoiding the side effects associated with NSAIDs. The compounds of Formula I represent a new chemical class with optimized pharmacological properties.
Solution Approach 2:
The patent develops novel small-molecule compounds that can be administered as temporary therapeutic agents. These compounds provide targeted modulation of gamma-secretase activity during the treatment period without the long-term harmful effects of NSAIDs, representing a disposable therapeutic approach rather than chronic supplementation.
2Reliability
If gamma-secretase modulators are developed to reduce Aβ42 production, then Alzheimer's disease progression is slowed, but CNS penetration is insufficient
Solution Approach 1:
The patent optimizes the physicochemical parameters of the compounds, including molecular weight, lipophilicity, and hydrogen bonding characteristics, to enhance blood-brain barrier penetration. The specific structural features in Formula I are designed to facilitate CNS delivery while maintaining gamma-secretase modulating activity.
Solution Approach 2:
The patent creates composite molecular structures combining aromatic hydrocarbon frameworks with polar amide groups and hydrophilic substituents. This composite architecture allows the compound to simultaneously achieve adequate CNS penetration through lipophilic regions while maintaining selective gamma-secretase modulation through polar interaction sites.
Data Source
AI summary
The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, R1 R2, R3, R4, R5, R6, R7, and R8 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with y-secretase activity, including Alzheimer´s disease.